Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.41 |
| ▸ | CCNK | O75909 | 2/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26987481 | 0.92 | SPR (0.40) | EPHX2CCNKCDK12GPR119CYP2C9 | |
| SCHEMBL14121158 | 0.92 | SPR (0.40) | EPHX2CCNKCDK12GPR119CYP2C9 | |
| SCHEMBL27130047 | 0.92 | SPR (0.40) | EPHX2CCNKCDK12GPR119CYP2C9 | |
| SCHEMBL30757104 | 0.92 | SPR (0.40) | EPHX2CCNKCDK12GPR119CYP2C9 | |
| SCHEMBL1066440 | 0.82 | GPR119 (0.56) | GPR119 | |
| SCHEMBL1982754 | 0.82 | GPR119 (0.55) | GPR119 | |
| SCHEMBL5267332 | 0.82 | MALT1 (0.45) | EPHX2CCNKCDK12CYP2C9CYP2J2 | |
| SCHEMBL5267084 | 0.81 | EPHX2 (0.41) | EPHX2CYP2C9CYP2J2 | |
| SCHEMBL25307709 | 0.80 | DGAT1 (0.44) | KMO | |
| SCHEMBL25307708 | 0.80 | DGAT1 (0.44) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2863916-B1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK SHARP & DOHME (US) | 2018-07-18 | — | — | EP | disclosed |
| EP-2884982-B1 | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9376418-B2 | Substituted pyridine spleen tyrosine kinase (SYK) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9353066-B2 | Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-20 | — | — | US | disclosed |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | MERCK CANADA INC. (CA) | 2015-05-28 | — | — | US | disclosed |
| WO-2012069852-A1 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE | ALMAC DISCOVERY LIMITED (GB) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232428-A1 | SUBSTITUTED PHENYL-SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | EPHX2 2513/4885CCNK 725/4885CDK12 1655/4885 |
| US-20150148327-A1 | SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS | SYK, BTK, LYN | EPHX2 2487/4885CCNK 568/4885CDK12 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.